Boerse Frankfurt :CWY

SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments

Retrieved on: 
Thursday, January 4, 2024
TEL, Psilocybin, Patent, CWY, MDMA, LSD, Lysergic acid diethylamide, IP, PEA, Central nervous system, Patient, Safety, Therapy, Disorder, DMT, Pharmaceutical industry

TEL AVIV, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, reflects on the successful collaboration in 2023 with  Clearmind Medicine Inc. (“Clearmind") (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems. Early in 2023, Clearmind filed six provisional patent applications with the United States Patent and Trademark Office (USPTO) for unique combinations of future psychedelic-based compounds, as part of its ongoing collaboration with SciSparc.

Key Points: 
  • Early in 2023, Clearmind filed six provisional patent applications with the United States Patent and Trademark Office (USPTO) for unique combinations of future psychedelic-based compounds, as part of its ongoing collaboration with SciSparc.
  • The patent applications are for novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA) and novel proprietary combinations of 3,4-Methylenedioxymethamphetamine (MDMA), Ibogaine, Ketamine, and PEA.
  • PEA is the active ingredient of SciSparc’s proprietary CannAmide™.
  • As part of the collaboration agreement between SciSparc and Clearmind, originally announced on March 8,2022, any assets generated from the collaboration shall be jointly owned by SciSparc and Clearmind.

SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.

Retrieved on: 
Tuesday, August 1, 2023
Patent, Extremities, CSE, Central nervous system, Therapy, Tic disorder, Face, United States Patent and Trademark Office, DSM-IV codes, Tourette syndrome, Dystonia, FSE, IP, TEL, Disorder, Parkinson's disease, CWY, Chorea, Pharmaceutical industry, Dyskinesia

The provisional patent application was filed with the United States Patent and Trademark Office.

Key Points: 
  • The provisional patent application was filed with the United States Patent and Trademark Office.
  • This patent application refers to combination of the psychedelic molecule 3-Methylmethcathinone, known as 3-MMC, and SciSparc's Palmitoylethanolamide as a potential treatment for dyskinesia.
  • This patent prospect corresponds well with SciSparc’s robust IP portfolio and some of the indications the Company is already pursuing such as Tourette Syndrome.
  • Our collaboration with Clearmind continues to bear fruit and emphasizes our commitment to pioneering innovative treatments for conditions with unmet need,” stated SciSparc’s Chief Executive Officer, Oz Adler.